Staining of BALB/c splenocytes with Anti-Human/Mouse CD45R (B220) FITC (Product # 11-0452) and 0.25 µg of Rat IgG2a K Isotype Control PE-Cyanine7 (Product # 25-4321) (left) or 0.25 µg of Anti-Mouse CD8a PE-Cyanine7 (right). Cells in the lymphocyte gate were used for analysis.
|Tested species reactivity||Mouse|
|Published species reactivity||Not Applicable|
|Host / Isotype||Rat / IgG2a, kappa|
|Storage buffer||PBS, pH 7.2, with 0.1% gelatin|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C, store in dark, DO NOT FREEZE!|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||0.5 µg/test|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Description: The 53-6.7 monoclonal antibody reacts with the mouse CD8a molecule. CD8a is an approximately 32-34 kDa cell surface receptor expressed either as a heterodimer with the CD8 beta chain (CD8 alpha beta) or as a homodimer (CD8 alpha alpha). A majority of thymocytes and a subpopulation of mature alpha beta TCR T cells express CD8 alpha beta while gamma delta TCR T cells, a subpopulation of intestinal intraepithelial lymphocytes (IELs) and dendritic cells express CD8 alpha alpha. CD8 binds to MHC class I and through its association with protein tyrosine kinase p56lck plays a role in T cell development and activation of mature T cells.
Applications Reported: The 53-6.7 antibody has been reported for use in flow cytometric analysis.
Applications Tested: This 53-6.7 antibody has been tested by flow cytometric analysis of mouse thymocytes and splenocytes. This can be used at less than or equal to 0.5 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.
Light sensitivity: This tandem dye is sensitive photo-induced oxidation. Please protect this vial and stained samples from light.
Fixation: Samples can be stored in IC Fixation Buffer (cat. 00-8222) (100 µL cell sample + 100 µL IC Fixation Buffer) or 1-step Fix/Lyse Solution (cat. 00-5333) for up to 3 days in the dark at 4°C with minimal impact on brightness and FRET efficiency/compensation. Some generalizations regarding fluorophore performance after fixation can be made, but clone specific performance should be determined empirically.
Excitation: 488-561 nm; Emission: 775 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser
CD8 molecule is composed of two chains termed alpha and beta. CD8 is found on a T cell subset of normal cytotoxic / suppressor cells which make up approximately 20 to 35 % of human peripheral blood lymphocytes. The CD8 antigen is also detected on natural killer cells, 80% of thymocytes, on a subpopulation of 30% of peripheral blood null cells and 15 to 30% of bone marrow cells.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
||Suppression of alkali burn-induced corneal neovascularization by dendritic cell vaccination targeting VEGF receptor 2.||Mochimaru H,Usui T,Yaguchi T,Nagahama Y,Hasegawa G,Usui Y,Shimmura S,Tsubota K,Amano S,Kawakami Y,Ishida S||Investigative ophthalmology and visual science (49:2172)||2008|
||Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes.||Yang Z,Day YJ,Toufektsian MC,Xu Y,Ramos SI,Marshall MA,French BA,Linden J||Circulation (114:2056)||2006|
|Not Applicable||Not Cited||Suppression of alkali burn-induced corneal neovascularization by dendritic cell vaccination targeting VEGF receptor 2.||Mochimaru H,Usui T,Yaguchi T,Nagahama Y,Hasegawa G,Usui Y,Shimmura S,Tsubota K,Amano S,Kawakami Y,Ishida S||Investigative ophthalmology and visual science (49:2172)||2008|
|Not Applicable||Not Cited||Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes.||Yang Z,Day YJ,Toufektsian MC,Xu Y,Ramos SI,Marshall MA,French BA,Linden J||Circulation (114:2056)||2006|